International Journal of Clinical Oncology

, Volume 18, Issue 6, pp 1042–1048 | Cite as

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

  • Ryota Nakanishi
  • Jun Harada
  • Munkhbold Tuul
  • Yan Zhao
  • Koji Ando
  • Hiroshi Saeki
  • Eiji Oki
  • Takefumi Ohga
  • Hiroyuki KitaoEmail author
  • Yoshihiro Kakeji
  • Yoshihiko Maehara
Original Article



Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor.


In this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated.


KRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC.


KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.


KRAS and BRAF mutations Colorectal cancer Prognostic factor 



We thank Ms. Noriko Makikusa and Ms. Naoko Katakura for their technical assistance.

Conflict of interest

We declare that we have no conflict of interest.


  1. 1.
    Takachi R, Tsubono Y, Baba K et al (2011) Red meat intake may increase the risk of colon cancer in Japanese, a population with relatively low red meat consumption. Asia Pac J Clin Nutr 20:603–612PubMedGoogle Scholar
  2. 2.
    Suzuki K, Muto T, Sawada T (1995) Prevention of local recurrence by extended lymphadenectomy for rectal cancer. Surg Today 25:795–801PubMedCrossRefGoogle Scholar
  3. 3.
    Kobayashi H, Mochizuki H, Kato T et al (2011) Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study. Int J Colorectal Dis 26:891–896PubMedCrossRefGoogle Scholar
  4. 4.
    De Roock W, De Vriendt V, Normanno N et al (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594–603PubMedCrossRefGoogle Scholar
  5. 5.
    Sylvester BE, Huo D, Khramtsov A et al (2012) Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:350–359Google Scholar
  6. 6.
    Uehara K, Ishiguro S, Hiramatsu K et al (2011) Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer. Jpn J Clin Oncol 41:1229–1232PubMedCrossRefGoogle Scholar
  7. 7.
    Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol 29:1050–1058PubMedCrossRefGoogle Scholar
  8. 8.
    Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRefGoogle Scholar
  10. 10.
    Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261PubMedCrossRefGoogle Scholar
  11. 11.
    Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRefGoogle Scholar
  12. 12.
    Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793PubMedCrossRefGoogle Scholar
  13. 13.
    Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856–862PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Jass JR, Sobin LH (1989) Histological typing of intestinal tumours. WHO international histological classification of tumours no. 15, 2nd edn. Springer, BerlinGoogle Scholar
  15. 15.
    Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  16. 16.
    Zhao Y, Miyashita K, Ando T et al (2008) Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. Gene 423:188–193PubMedCrossRefGoogle Scholar
  17. 17.
    Oda S, Oki E, Maehara Y, Sugimachi K (1997) Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res 25:3415–3420PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancer––the stable evidence. Nat Rev Clin Oncol 7:153–162PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Bando H, Yoshino T, Tsuchihara K et al (2011) KRAS mutations detected by the amplification refractory mutation system––Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 105:403–406PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Watanabe T, Kobunai T, Yamamoto Y et al (2011) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47:1946–1954PubMedCrossRefGoogle Scholar
  21. 21.
    George B, Kopetz S (2011) Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep 13:206–215PubMedCrossRefGoogle Scholar
  22. 22.
    Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kelley L, Silverstein M, Guerra L (2011) Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index. Ann Surg Oncol 18:459–462PubMedCrossRefGoogle Scholar
  24. 24.
    Greenberg PL, Attar E, Bennett JM et al (2011) NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw 9:30–56Google Scholar
  25. 25.
    Van Cutsem E, Oliveira J (2009) Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 20(Suppl 4):49–50PubMedGoogle Scholar
  26. 26.
    Komatsu Y (2007) Adjuvant chemotherapy for colorectal cancer in Japan––current state and problem areas. Gan To Kagaku Ryoho 34:799–807PubMedGoogle Scholar
  27. 27.
    Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466–474PubMedCrossRefGoogle Scholar
  28. 28.
    Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261–1270PubMedCrossRefGoogle Scholar
  29. 29.
    Deschoolmeester V, Boeckx C, Baay M et al (2010) KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 103:1627–1636PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Kanemitsu M, Ueno H, Naito K et al (2012) A case of paraneoplastic limbic encephalitis associated with malignant lymphoma presenting with a late-onset bilateral thalamic lesion. Brain Nerve 64:71–77PubMedGoogle Scholar
  31. 31.
    Bertagnolli MM, Redston M, Compton CC et al (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer—a study of CALGB 9581 and 89803. J Clin Oncol 29:3153–3162PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Elsaleh H, Joseph D, Grieu F et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750PubMedCrossRefGoogle Scholar
  33. 33.
    Bakin AV, Curran T (1999) Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 283:387–390PubMedCrossRefGoogle Scholar
  34. 34.
    Ordway JM, Williams K, Curran T (2004) Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23:3737–3748PubMedCrossRefGoogle Scholar
  35. 35.
    van Engeland M, Derks S, Smits KM et al (2011) Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29:1382–1391PubMedCrossRefGoogle Scholar
  36. 36.
    Lievre A, Rouleau E, Buecher B, Mitry E (2010) Clinical significance of BRAF mutations in colorectal cancer. Bull Cancer 97:1441–1452PubMedGoogle Scholar
  37. 37.
    Wong R, Cunningham D (2008) Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26:5668–5670PubMedCrossRefGoogle Scholar
  38. 38.
    Compton CC (1999) Pathology report in colon cancer: what is prognostically important? Dig Dis 17:67–79PubMedCrossRefGoogle Scholar
  39. 39.
    Takeuchi K, Kuwano H, Tsuzuki Y et al (2004) Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology 51:1698–1702PubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2012

Authors and Affiliations

  • Ryota Nakanishi
    • 1
    • 2
  • Jun Harada
    • 1
  • Munkhbold Tuul
    • 1
    • 2
  • Yan Zhao
    • 1
  • Koji Ando
    • 1
  • Hiroshi Saeki
    • 1
  • Eiji Oki
    • 1
  • Takefumi Ohga
    • 1
  • Hiroyuki Kitao
    • 2
    Email author
  • Yoshihiro Kakeji
    • 1
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Molecular Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations